TickerFacts.

Company research / RNTX

Rein Therapeutics, Inc. (RNTX)

Build a valuation ↗↓ Download CSV

CIK 0001420565 · Nasdaq · Pharmaceutical Preparations

  • Sector Manufacturing
  • Fiscal year ends Dec 31

For the year ended 2025-12-31, Rein Therapeutics, Inc. reported revenue of $0.

Key ratios (year ended 2025-12-31)

-294.8%
Return on year-end equity

Beyond the statements

Follow the company.

Explore new filings, reported insider transactions and company relationships.

Open company research ↗

Latest selected filing: 8-K · 2026-09-04

Price chart

Chart and quotes by TradingView. Exchange coverage and delays vary.

Open chart on TradingView

Annual financials

Annual flows and balances are grouped by their actual period end. Select a figure to open its SEC filing. A dash means a matching observation is unavailable.

Period ended2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-31
Revenue$0$0$0$0$0$0$0$0$0—
Operating Income-$50.63M-$65.11M-$16.28M-$27.65M-$26.61M-$20.50M-$29.96M-$31.90M-$23.01M-$18.17M
Net Income-$49.87M-$62.88M-$15.73M-$27.33M-$26.16M-$27.33M-$29.37M-$31.55M-$22.60M-$18.12M
EPS (Diluted)$-1.96$-3.51$-3.42$-6.02$-5.89—————
Total Assets$24.16M$62.19M$106.01M$22.01M$48.48M$16.34M$26.47M$30.31M$52.69M$22.02M
Total Liabilities$7.24M$7.80M$7.71M$3.38M$4.58M$4.18M$10.43M$10.71M$4.89M$4.08M
Shareholders' Equity$16.92M$54.39M$98.30M$18.62M$43.90M$12.16M$16.05M$19.60M$47.80M-$111.81M
Cash & Equivalents$3.21M$12.87M$17.34M$5.19M$3.60M$7.05M$5.31M$10.63M$11.86M$20.71M
Operating Cash Flow-$19.36M-$22.29M-$19.81M-$24.86M-$23.75M-$20.48M-$26.47M-$27.93M-$20.53M—
Capital Expenditures————$157.0K$5.0K$151.0K$4.42M$142.0K—
Shares Outstanding27.55M21.67M4.89M4.54M4.53M43.80M27.81M14.75M14.72M432.4K
Dividends Per Share$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00
Weighted Average Diluted Shares25.44M17.94M4.60M4.54M4.44M—————
EPS (Basic)$-1.96$-3.51$-3.42$-6.02$-5.89—————